Scarica l'app Stockscreener
74.93
1.91%
-1.46
Dopo l'orario di chiusura:
74.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
ViaSat, Arrowhead Pharmaceuticals, and Sphere Entertainment Lead Stock Returns - Markets Mojo
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals - Arrowhead Pharmaceuticals, Inc.
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology
Arrowhead Pharmaceuticals stock hits 52-week high at 77.23 USD - Investing.com
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Canada
After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan
JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com
MSN Money - MSN
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events - Business Wire
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS - Yahoo Finance
Arrowhead upgraded at Morgan Stanley on upcoming catalysts - MSN
Is Arrowhead Pharmaceuticals (ARWR) Stock Price Out Of Line With Recent 1-Year Surge? - Sahm
Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential - Insider Monkey
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc. - MarketBeat
ARWR Initiates Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus
ARWR SEC FilingsArrowhead Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by JPMorgan Chase & Co. - MarketBeat
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
J.P. Morgan Initiates Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $88 - Moomoo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating - Investing.com
JP Morgan Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Overweight Recommendation - MSN
Arrowhead Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
5 Most Profitable Biotech Stocks to Buy Now - Insider Monkey
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Behavioral Patterns of ARWR and Institutional Flows - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Thursday - MarketBeat
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Vanguard reports 5.05% stake in Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Pictet Asset Management Holding SA - MarketBeat
Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead - Stock Titan
FengHe Fund Management Pte. Ltd. Makes New $17.71 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead rises as FDA approves lead drug for rare disorder - msn.com
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe - marketscreener.com
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Arrowhead Pharmaceuticals (ARWR) price target increased by 23.01% to 77.60 - MSN
Insider Sell: James Hamilton Sells 10,000 Shares of Arrowhead Ph - GuruFocus
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 10,000 Shares of Stock - MarketBeat
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 pre-planned shares - Stock Titan
Arrowhead CFO Daniel Apel sells $934,285 in company stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock - Investing.com UK
Arrowhead CFO Daniel Apel sells $934,285 in company stock - Investing.com
Arrowhead (ARWR) CFO Apel sells 13,095 shares in Rule 10b5-1 trades - Stock Titan
BlackRock holds 12.2% of Arrowhead Pharmaceuticals (NASDAQ: ARWR) in 13G/A - Stock Titan
Sanofi, Arrowhead, Novartis win CHMP backing (SNY:NASDAQ) - Seeking Alpha
Arrowhead (ARWR) Secures Positive EMA Opinion for REDEMPLO in FC - GuruFocus
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe - Arrowhead Pharmaceuticals, Inc.
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):